Clinical trial
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
NCT04866667
Study timeline
Study start (actual)2021-05-01Date precision: day
Registry last updated2026-04-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 2 Diabetes Mellitusunresolved
Arteriosclerotic Cardiovascular Diseaseunresolved
Liraglutideunresolved
Interventions
Sponsors & collaborators
Zhejiang Provincial People's Hospitallead sponsor
Ningbo Medical Center Lihuili Hospitalcollaborator
Putuo People's Hospitalcollaborator
The Second People's Hospital of Yuhuancollaborator
ShuGuang Hospitalcollaborator
Affiliated Hospital of Jiaxing Universitycollaborator
Nanxun People's Hospitalcollaborator
The First People's Hospital of Huzhoucollaborator
Zhejiang Greentown Cardiovascular Hospitalcollaborator
Red Cross Hospital, Hangzhou, Chinacollaborator
The Second School of Medicine，WMUcollaborator
The First People's Hospital of Xiaoshancollaborator
Zhejiang Hospitalcollaborator
Yiwu Central Hospitalcollaborator
Quzhou Hospitalcollaborator
Jinhua Hospital of TCMcollaborator
Shaoxing Central Hospitalcollaborator
Shaoxinig Second Hospitalcollaborator
Chinese Academy of Sciencescollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04866667 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.